%0 Journal Article %T Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review %+ Prince of Wales Clinical School [Sydney, Australia] %+ School of Social Sciences [Kensington, Australia] %+ Department of Obstetrics and Oncology [Melbourne, Australia] %+ Institut Paoli-Calmettes (IPC) %+ Familial Cancer Service [Westmead, Australia] %+ The Westmead Institute for Medical Research %+ Sir Peter MacCallum Department of Oncology [Parkville, VIC, Australia] %+ Familial Cancer Centre [Melbourne, VIC, Australia] %A Meiser, Bettina %A Wong, W. K. Tim %A Peate, Michelle %A Julian-Reynier, Claire %A Kirk, Judy %A Mitchell, Gillian %Z This work was funded by a Strategic Partnership Grant from Cancer Council of New South Wales (ID SRP 13–02). Bettina Meiser is supported Senior Research Fellowship Level B (ID 1078523) from the National Health and Medical Research Council Australia. Michelle Peate is currently supported by a National Breast Cancer Foundation Early Career Fellowship (ECG-15-005). %< avec comité de lecture %@ 1897-4287 %J Hereditary Cancer in Clinical Practice %I BioMed Central %V 15 %N 1 %P 14 %8 2016-12 %D 2016 %R 10.1186/s13053-017-0075-8 %M 28943990 %K Tamoxifen %K Prevention %K Risk-reducing medication %K Breast cancer %K High risk %Z Life Sciences [q-bio]Journal articles %X AbstractBackgroundSelective estrogen receptor modulators, such as tamoxifen, reduce breast cancer risk by up to 50% in women at increased risk for breast cancer. Despite tamoxifen’s well-established efficacy, many studies show that most women are not taking up tamoxifen. This systematic literature review aimed to identify the motivators and barriers to tamoxifen use ‘s amongst high-risk women.MethodsUsing MEDLINE, PsycINFO, and Embase plus reviewing reference lists of relevant articles published between 1995 and 2016, 31 studies (published in 35 articles) were identified, which addressed high-risk women’s decisions about risk-reducing medication to prevent breast cancer and were peer-reviewed primary clinical studies.ResultsA range of factors were identified as motivators of, and barriers to, tamoxifen uptake including: perceived risk, breast-cancer-related anxiety, health professional recommendation, perceived drug effectiveness, concerns about side-effects, knowledge and access to information about side-effects, beliefs about the role of risk-reducing medication, provision of a biomarker, preference for other forms of breast cancer risk reduction, previous treatment experience, concerns about randomization in clinical trial protocols and finally altruism.ConclusionsResults indicate that the decision for high-risk women regarding tamoxifen use or non-use as a risk-reducing medication is not straightforward. Support of women making this decision is essential and needs to encompass the full range of factors, both informational and psychological. %G English %2 https://inserm.hal.science/inserm-01592400/document %2 https://inserm.hal.science/inserm-01592400/file/13053_2017_Article_75.pdf %L inserm-01592400 %U https://inserm.hal.science/inserm-01592400 %~ INSERM